Compare ADMA Biologics Inc (ADMA) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs TJX Companies Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while TJX Companies Inc trades at $153.18 (market cap $170.25B). The key difference: TJX Companies Inc is far larger — about 79.9× ADMA Biologics Inc's market cap, and TJX Companies Inc pays a 1.25% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TJX | |
|---|---|---|
Market Cap | $2.13B | $170.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $168.41 |
52-Week Low | $7.60 | $121.35 |
Enterprise Value | $2.20B | $178.85B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TJX trades at $154.11, up slightly by 0.02% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate, and maintains robust profitability with a 61.25% ROE. Revenue growth is steady, reaching $56.36B in 2025, supported by expansion in home goods and international markets.
Outlook remains positive with an 88% analyst buy rating and a $181.80 consensus price target, implying 18% upside. Risks include high valuation multiples like a 29.44 P/E and economic sensitivity, but strong cash flow and dividend payments provide stability. Investors should monitor Q2 2026 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
